Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD

医学 拜瑞妥 阿司匹林 血运重建 外科 危险系数 心肌梗塞 氯吡格雷 临床终点 冲程(发动机) 溶栓 截肢 内科学 随机对照试验 心脏病学 华法林 心房颤动 置信区间 工程类 机械工程
作者
Jennifer A. Rymer,Sonia S. Anand,E. Sebastian Debus,Lloyd Haskell,Connie N. Hess,W. Schuyler Jones,Eva Muehlhofer,Scott D. Berkowitz,Rupert Bauersachs,Marc P. Bonaca,Manesh R. Patel
出处
期刊:Circulation [Lippincott Williams & Wilkins]
卷期号:148 (24): 1919-1928 被引量:10
标识
DOI:10.1161/circulationaha.122.063806
摘要

BACKGROUND: Rivaroxaban plus aspirin compared with aspirin alone reduced major cardiac and ischemic limb events after lower extremity revascularization (LER) in the VOYAGER PAD (Vascular Outcomes Study of ASA Along With Rivaroxaban in Endovascular or Surgical Limb Revascularization for Peripheral Artery Disease) trial. The effect has not been described in patients undergoing endovascular LER. METHODS: The VOYAGER PAD trial randomized 6564 patients with symptomatic peripheral artery disease to a double-blinded treatment with 2.5 mg of rivaroxaban BID or matching placebo and 100 mg of aspirin daily. The primary efficacy outcome was a composite of acute limb ischemia, major amputation of a vascular pathogenesis, myocardial infarction, ischemic stroke, or cardiovascular death. The principal safety end point was Thrombolysis in Myocardial Infarction major bleeding. A prespecified subgroup of patients who underwent endovascular revascularization was included. RESULTS: Endovascular LER occurred in 4379 (66.7%) patients and surgical LER in 2185 (33.3%). Over a 3-year follow-up, rivaroxaban reduced the risk of the primary outcome by 15% (hazard ratio [HR], 0.85 [95% CI, 0.76–0.96]) with an absolute risk reduction of 0.92% at 6 months and 1.04% at 3 years and a consistent benefit in those receiving endovascular (HR, 0.89 [95% CI, 0.76–1.03]) or surgical LER (HR, 0.81 [95% CI, 0.67–0.98]; P interaction=0.43). For endovascular-treated patients, rivaroxaban reduced the risk of acute limb ischemia or major amputation of a vascular pathogenesis by 30% (HR, 0.70 [95% CI, 0.54–0.90]; P =0.005) with an absolute risk reduction of 1.0% at 6 months and 2.0% at 3 years compared with aspirin alone. Among endovascular-treated patients, the median duration of concomitant dual antiplatelet therapy with clopidogrel treatment was 31 days (interquartile range, 30–58). There was a consistent benefit for rivaroxaban regardless of background clopidogrel. Thrombolysis in Myocardial Infarction major bleeding was significantly higher for the rivaroxaban and aspirin group for the endovascular cohort (HR, 1.66 [95% CI, 1.06–2.59]) with an absolute risk increase of 0.9% at 3 years with no increase in intracranial or fatal bleeding observed (HR, 0.86 [95% CI, 0.40–1.87]; P =0.71). Mortality with rivaroxaban was higher in the endovascular-treated patients (HR, 1.24 [95% CI, 1.02–1.52]), although this finding was isolated to specific regions. CONCLUSIONS: Rivaroxaban added to aspirin or dual antiplatelet therapy after LER for peripheral artery disease reduces ischemic risk and increases major bleeding without an increased risk of intracranial or fatal bleeding. These benefits are consistent in those treated with endovascular and surgical approaches with significant benefits for major adverse limb events. These data support the use of rivaroxaban in addition to aspirin or dual antiplatelet therapy after endovascular intervention for symptomatic peripheral artery disease.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
5秒前
Likz完成签到,获得积分10
5秒前
不安的秋白完成签到,获得积分10
7秒前
清新的剑心完成签到 ,获得积分10
8秒前
Yiling完成签到,获得积分10
8秒前
10秒前
氕氘氚完成签到 ,获得积分10
14秒前
Hello应助不安的秋白采纳,获得10
16秒前
糯米团的完成签到 ,获得积分10
17秒前
神勇从波完成签到 ,获得积分10
19秒前
yellow完成签到 ,获得积分10
21秒前
虚幻元风完成签到 ,获得积分10
24秒前
xybjt完成签到 ,获得积分10
27秒前
巴达天使完成签到,获得积分10
33秒前
江三村完成签到 ,获得积分10
33秒前
量子星尘发布了新的文献求助10
51秒前
CyberHamster完成签到,获得积分10
1分钟前
xiaohong完成签到,获得积分10
1分钟前
朱比特完成签到,获得积分10
1分钟前
1分钟前
zmuzhang2019发布了新的文献求助10
1分钟前
onestepcloser完成签到 ,获得积分0
1分钟前
zoe完成签到 ,获得积分10
1分钟前
发嗲的慕蕊完成签到 ,获得积分10
1分钟前
Linson完成签到,获得积分10
1分钟前
顾矜应助赵三岁采纳,获得10
1分钟前
yyy2025完成签到,获得积分10
1分钟前
木雨亦潇潇完成签到,获得积分10
1分钟前
香蕉觅云应助nine2652采纳,获得10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
芳华如梦完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
土豆丝完成签到 ,获得积分10
1分钟前
琦琦完成签到,获得积分10
1分钟前
zzzz完成签到,获得积分20
2分钟前
GEZIKU完成签到 ,获得积分10
2分钟前
2分钟前
2分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038039
求助须知:如何正确求助?哪些是违规求助? 3575756
关于积分的说明 11373782
捐赠科研通 3305574
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022